111 related articles for article (PubMed ID: 38199284)
1. Worsening of 2-year patient-reported intestinal functionality after radiotherapy for prostate cancer including pelvic node irradiation.
Sanguineti G; Pavarini M; Munoz F; Magli A; Cante D; Garibaldi E; Gebbia A; Noris Chiorda B; Girelli G; Villa E; Faiella A; Magdalena Waskiewicz J; Avuzzi B; Pastorino A; Moretti E; Rago L; Statuto T; Gatti M; Rancati T; Valdagni R; Luigi Vavassori V; Gisella Di Muzio N; Fiorino C; Cozzarini C
Radiother Oncol; 2024 Mar; 192():110088. PubMed ID: 38199284
[TBL] [Abstract][Full Text] [Related]
2. Acute patient-reported intestinal toxicity in whole pelvis IMRT for prostate cancer: Bowel dose-volume effect quantification in a multicentric cohort study.
Bresolin A; Faiella A; Garibaldi E; Munoz F; Cante D; Vavassori V; Waskiewicz JM; Girelli G; Avuzzi B; Villa E; Magli A; Noris Chiorda B; Gatti M; Ferella L; Maggio A; Landoni V; Aimonetto S; Sini C; Rancati T; Sanguineti G; Valdagni R; Di Muzio N; Fiorino C; Cozzarini C
Radiother Oncol; 2021 May; 158():74-82. PubMed ID: 33639190
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported intestinal toxicity from whole pelvis intensity-modulated radiotherapy: First quantification of bowel dose-volume effects.
Sini C; Noris Chiorda B; Gabriele P; Sanguineti G; Morlino S; Badenchini F; Cante D; Carillo V; Gaetano M; Giandini T; Landoni V; Maggio A; Perna L; Petrucci E; Sacco V; Valdagni R; Rancati T; Fiorino C; Cozzarini C
Radiother Oncol; 2017 Aug; 124(2):296-301. PubMed ID: 28739383
[TBL] [Abstract][Full Text] [Related]
4. Hyperbaric oxygen for patients with chronic bowel dysfunction after pelvic radiotherapy (HOT2): a randomised, double-blind, sham-controlled phase 3 trial.
Glover M; Smerdon GR; Andreyev HJ; Benton BE; Bothma P; Firth O; Gothard L; Harrison J; Ignatescu M; Laden G; Martin S; Maynard L; McCann D; Penny CEL; Phillips S; Sharp G; Yarnold J
Lancet Oncol; 2016 Feb; 17(2):224-233. PubMed ID: 26703894
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported acute fatigue in elderly breast cancer patients treated with and without regional nodal radiation.
Misra S; Lee G; Korzets Y; Wang L; Lau A; Koch CA; Croke J; Helou J
Breast Cancer Res Treat; 2020 Sep; 183(2):391-401. PubMed ID: 32651754
[TBL] [Abstract][Full Text] [Related]
6. Quality of life after whole pelvic versus prostate-only external beam radiotherapy for prostate cancer: a matched-pair comparison.
Pinkawa M; Piroth MD; Holy R; Fischedick K; Klotz J; Székely-Orbán D; Eble MJ
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):23-8. PubMed ID: 20832182
[TBL] [Abstract][Full Text] [Related]
7. Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL).
Dearnaley D; Griffin CL; Lewis R; Mayles P; Mayles H; Naismith OF; Harris V; Scrase CD; Staffurth J; Syndikus I; Zarkar A; Ford DR; Rimmer YL; Horan G; Khoo V; Frew J; Venkitaraman R; Hall E
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(3):605-617. PubMed ID: 30528653
[TBL] [Abstract][Full Text] [Related]
8. A modified inflammatory bowel disease questionnaire and the Vaizey Incontinence questionnaire are more sensitive measures of acute gastrointestinal toxicity during pelvic radiotherapy than RTOG grading.
Khalid U; McGough C; Hackett C; Blake P; Harrington KJ; Khoo VS; Tait D; Norman AR; Andreyev HJ
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1432-41. PubMed ID: 16580497
[TBL] [Abstract][Full Text] [Related]
9. Association between pelvic nodal radiotherapy and patient-reported functional outcomes through 5 years among men undergoing external-beam radiotherapy for prostate cancer: An assessment of the comparative effectiveness analysis of surgery and radiation (CEASAR) cohort.
Wallis CJD; Huang LC; Zhao Z; Penson DF; Koyama T; Conwill R; Tallman JE; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Barocas DA; Hoffman KE
Urol Oncol; 2022 Feb; 40(2):56.e1-56.e8. PubMed ID: 34154899
[TBL] [Abstract][Full Text] [Related]
10. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
11. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial.
Yeoh EE; Fraser RJ; McGowan RE; Botten RJ; Di Matteo AC; Roos DE; Penniment MG; Borg MF
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):943-55. PubMed ID: 12605972
[TBL] [Abstract][Full Text] [Related]
12. A modified Inflammatory Bowel Disease questionnaire and the Vaizey Incontinence questionnaire are simple ways to identify patients with significant gastrointestinal symptoms after pelvic radiotherapy.
Olopade FA; Norman A; Blake P; Dearnaley DP; Harrington KJ; Khoo V; Tait D; Hackett C; Andreyev HJ
Br J Cancer; 2005 May; 92(9):1663-70. PubMed ID: 15856043
[TBL] [Abstract][Full Text] [Related]
13. Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience.
Hamstra DA; Conlon AS; Daignault S; Dunn RL; Sandler HM; Hembroff AL; Zietman AL; Kaplan I; Ciezki J; Kuban DA; Wei JT; Sanda MG; Michalski JM;
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):546-53. PubMed ID: 23561651
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported quality of life during radiation treatment for localized prostate cancer: results from a prospective phase II trial.
Chen RC; Zhang Y; Chen MH; McMahon E; Loffredo M; McPherson CP; Nguyen AU; Nguyen PL; D'Amico AV
BJU Int; 2012 Dec; 110(11):1690-5. PubMed ID: 22502770
[TBL] [Abstract][Full Text] [Related]
15. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
[TBL] [Abstract][Full Text] [Related]
16. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population.
Hanlon AL; Watkins Bruner D; Peter R; Hanks GE
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):51-9. PubMed ID: 11163497
[TBL] [Abstract][Full Text] [Related]
17. Toxicity of Pelvic Lymph Node Irradiation With Intensity Modulated Radiation Therapy for High-Risk and Locally Advanced Prostate Cancer: A National Population-Based Study Using Patient-Reported Outcomes.
Parry MG; Nossiter J; Cowling TE; Sujenthiran A; Berry B; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1196-1203. PubMed ID: 32717261
[TBL] [Abstract][Full Text] [Related]
18. Late fecal incontinence after high-dose radiotherapy for prostate cancer: better prediction using longitudinal definitions.
Fiorino C; Rancati T; Fellin G; Vavassori V; Cagna E; Casanova Borca V; Girelli G; Menegotti L; Monti AF; Tortoreto F; Delle Canne S; Valdagni R
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):38-45. PubMed ID: 21985939
[TBL] [Abstract][Full Text] [Related]
19. Structured gastroenterological intervention and improved outcome for patients with chronic gastrointestinal symptoms following pelvic radiotherapy.
Henson CC; Davidson SE; Ang Y; Babbs C; Crampton J; Kelly M; Lal S; Limdi JK; Whatley G; Swindell R; Makin W; McLaughlin J
Support Care Cancer; 2013 Aug; 21(8):2255-65. PubMed ID: 23512314
[TBL] [Abstract][Full Text] [Related]
20. Comparing bowel and urinary domains of patient-reported quality of life at the end of and 3 months post radiotherapy between intensity-modulated radiotherapy and proton beam therapy for clinically localized prostate cancer.
Bai M; Gergelis KR; Sir M; Whitaker TJ; Routman DM; Stish BJ; Davis BJ; Pisansky TM; Choo R
Cancer Med; 2020 Nov; 9(21):7925-7934. PubMed ID: 32931662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
